Ardsley Advisory Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Ardsley Advisory Partners’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-25,000	Closed	-$93K	–	197
2017 Q4	$93K	Buy	+25,000	New	+$102K	0.01%	134

Ardsley Advisory Partners's CASC Position: Q1 2018 in Review

Ardsley Advisory Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 25,000 shares — an estimated $93K sold.

Ardsley Advisory Partners first reported a position in CASC in Q4 2017 and held it in 1 quarter. The position peaked at $93K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Ardsley Advisory Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 25,000 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $93K.
Ardsley Advisory Partners first reported a position in Cascadian Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Ardsley Advisory Partners's Cascadian Therapeutics, Inc. position peaked at $93K in Q4 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.